CEO Ben Palleiko expressed optimism about the ongoing launch of EKTERLY, highlighting the increasing real-world experience and demand for the treatment. The company plans to continue its expansion efforts, including a pediatric filing for patients aged 2-11 later this year. KalVista's financial results indicate a robust operational execution, with a focus on expanding access to EKTERLY worldwide. The company is also preparing for a conference call to discuss these results in detail, scheduled for today at 8:30 AM ET.
2026-03-25 11:19:44
KalVista Pharmaceuticals Reports $49.1 Million Revenue for EKTERLY in Transition Period Ending December 31, 2025
Expected Stock impact: Noticeably Positive
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) has announced its financial results for the eight-month transition period ending December 31, 2025. The company reported a significant global net product revenue of $49.1 million from EKTERLY (sebetralstat), the first and only oral on-demand treatment for hereditary angioedema (HAE). This revenue reflects the strong market adoption of EKTERLY, with 1,702 patient start forms received in the U.S. since its launch in July 2025. The company has also noted the successful launch of EKTERLY in Japan by its partner, Kaken Pharmaceutical Co., Ltd., further expanding its market reach.
CEO Ben Palleiko expressed optimism about the ongoing launch of EKTERLY, highlighting the increasing real-world experience and demand for the treatment. The company plans to continue its expansion efforts, including a pediatric filing for patients aged 2-11 later this year. KalVista's financial results indicate a robust operational execution, with a focus on expanding access to EKTERLY worldwide. The company is also preparing for a conference call to discuss these results in detail, scheduled for today at 8:30 AM ET.
CEO Ben Palleiko expressed optimism about the ongoing launch of EKTERLY, highlighting the increasing real-world experience and demand for the treatment. The company plans to continue its expansion efforts, including a pediatric filing for patients aged 2-11 later this year. KalVista's financial results indicate a robust operational execution, with a focus on expanding access to EKTERLY worldwide. The company is also preparing for a conference call to discuss these results in detail, scheduled for today at 8:30 AM ET.
